1

Publications

CD73 INHIBITOR PROGRAM: ORIC-533

ORIC publications

Preliminary Results of the Oral CD73 Inhibitor, ORIC-533, in Relapsed/Refractory Multiple Myeloma (RRMM)
Poster presented at: 2023 American Society of Hematology Annual Meeting, December 9-12, 2023. Poster #4761
CD73 inhibition reverses immunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma
Poster presented at: 2022 American Society of Hematology Annual Meeting, December 10-13, 2022. Poster #4472
ORIC-533, a Small Molecule CD73 Inhibitor with Best-in-Class Properties, Reverses Immunosuppression and Has Potential as an Immunomodulatory Therapy in Patients with Multiple Myeloma
Poster presented at: 2022 American Association for Cancer Research Annual Meeting, April 8-13, 2022. Abstract # 2074
Blocking Adenosine Production with ORIC-533, a CD73 Inhibitor with Best-In-Class Properties, Reverses Immunosuppression in High-AMP Environments
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract # LB-163
CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cell activation
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #1023
An orally bioavailable inhibitor of CD73 reverts intratumoral immunosuppression and promotes anti-tumor response
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #LB-115
Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production
Poster presented at: 2020 American Association for Cancer Research; April 27, 2020. Abstract #1242, presentation 1037.
Intratumoral immunosuppression is reversed by blocking adenosine production with an oral inhibitor of CD73
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A19.

EGFR/HER2 INHIBITOR PROGRAM: ORIC-114

ORIC publications

A Global Phase 1b Study of ORIC-114, a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Patients with Advanced Solid Tumors Harboring EGFR and HER2 Exon 20 or HER2 Alterations
Poster presented at: ESMO Congress 2023, October 20-24, 2023. Poster #1333P
Preclinical Activity of ORIC-114, a Highly Selective, Brain Penetrant, Irreversible Kinase Inhibitor, Against Atypical Mutations in EGFR
Poster presented at: ESMO Congress 2023, October 20-24, 2023. Poster #1345P
ORIC-114, an Orally Bioavailable, Irreversible Kinase Inhibitor, Has Superior Brain Penetration and Antitumor Activity in Subcutaneous and Intracranial NSCLC Models
Poster presented at: 2022 American Association for Cancer Research Annual Meeting, April 8-13, 2022. Abstract #3335
ORIC-114, an Orally Bioavailable, Irreversible Kinase Inhibitor, Has Superior Brain Penetrant Properties and Enhanced Potency in Preclinical Studies of HER2-Positive Breast Cancer
Poster presented at: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021. Poster # P234
ORIC-114, a Brain Penetrant, Orally Bioavailable, Irreversible Inhibitor Selectively Targets EGFR and HER2 Exon 20 Insertion Mutants and Regresses Intracranial NSCLC Xenograft Tumors
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract #1466

PRC2 INHIBITOR PROGRAM: ORIC-944

ORIC publications

ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models
Presented at: 2024 American Association for Cancer Research Annual Meeting, April 5-10, 2024. Abstract #6856
Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer
Presented at: 2024 American Association for Cancer Research Annual Meeting, April 5-10, 2024.
Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer
Poster presented at: 2023 American Association for Cancer Research Annual Meeting, April 14-19, 2023. Abstract #2791
ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Demonstrates Robust In Vivo Activity in Prostate Cancer Models
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract #1131

PLK4 INHIBITOR PROGRAM

ORIC publications

ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models
Poster presented at: 2024 American Association for Cancer Research Annual Meeting, April 5-10, 2024. Abstract #594
Selective PLK4 Inhibitors Demonstrate Synthetic Lethality in TRIM37 Amplified Neuroblastoma and Breast Cancer Models While Less Selective Inhibitors Do Not
Poster presented at: 2023 American Association for Cancer Research Annual Meeting, April 14-19, 2023. Abstract #4998
Discovery of Novel, Highly Selective Inhibitors of PLK4 That Demonstrate In Vivo Regressions in TRIM37 High Xenografts
Poster presented at: 2022 American Association for Cancer Research Annual Meeting, April 8-13, 2022. Abstract #2633